Gene polymorphisms impact the risk of rejection with hemodynamic compromise: A multicenter study

Transplantation

Volumn 91, Issue 12, 2011, Pages 1326-1332

  Girnita, Diana M ^a   Ohmann, Erin L ^a   Brooks, Maria M ^b   Webber, Steven A ^a   Burckart, Gilbert J ^c   Ferrell, Robert E ^d   Ranganathan, Sarangarajan ^e   Chinnock, Richard ^f   Canter, Charles ^g   Addonizio, Linda ^h   Bernstein, Daniel ⁱ   Kirklin, James K ^j   Naftel, David C ^j   Zeevi, Adriana ^a,k  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^f LOMA LINDA UNIVERSITY   (United States)

^g ST LOUIS CHILDREN S HOSPITAL   (United States)

^h Och Spine at New York Presbyterian Hospitals   (United States)

ⁱ STANFORD UNIVERSITY   (United States)

^j Kentucky   (United States)

^k Department of Pathology   (United States)

more..

Author keywords

Clinical outcome; Genetic polymorphism; Hemodynamic compromise; Pediatric heart transplant; Rejection

Indexed keywords

ADENINE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYTOSINE; DIPEPTIDYL CARBOXYPEPTIDASE; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; GUANINE; INOTROPIC AGENT; INTERLEUKIN 10; INTERLEUKIN 6; THYMINE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A;

ACE GENE; ADJUVANT THERAPY; ADOLESCENT; AGE; ARTICLE; CARDIAC GRAFT REJECTION; CHILD; DNA POLYMORPHISM; FAS GENE; FASL GENE; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; GRAFT RECIPIENT; HEART DISEASE; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IL10 GENE; IL6 GENE; INF GAMMA GENE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RACE; REJECTION WITH HEMODYNAMIC COMPROMISE; RISK ASSESSMENT; RISK REDUCTION; TNF ALPHA GENE; VEGF A GENE;

ADOLESCENT; APOPTOSIS; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; GRAFT REJECTION; HEART TRANSPLANTATION; HEMODYNAMICS; HUMANS; IMMUNE SYSTEM; INFANT; INTERLEUKIN-10; MALE; MODELS, GENETIC; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RISK;

EID: 79958716523     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31821c1e10     Document Type: Article

References (30)

1. Canter C, Naftel D, Caldwell R, et al. Survival and risk factors for death after cardiac transplantation in infants. A multi-institutional study. The Pediatric Heart Transplant Study. Circulation 1997; 96: 227.
2. Chin C, Naftel DC, Singh TP, et al. Risk factors for recurrent rejection in pediatric heart transplantation: A multicenter experience. J Heart Lung Transplant 2004; 23: 178.
3. Webber SA, Naftel DC, Parker J, et al. Late rejection episodes more than 1 year after pediatric heart transplantation: Risk factors and outcomes. J Heart Lung Transplant 2003; 22: 869.
4. Gossett JG, Canter CE, Zheng J, et al. Decline in rejection in the first year after pediatric cardiac transplantation: A multi-institutional study. J Heart Lung Transplant 2010; 29: 625.
5. Mills RM, Naftel DC, Kirklin JK, et al. Heart transplant rejection with hemodynamic compromise: A multiinstitutional study of the role of endomyocardial cellular infiltrate. Cardiac Transplant Research Database. J Heart Lung Transplant 1997; 16: 813.
6. Pahl E, Naftel DC, Canter CE, et al. Death after rejection with severe hemodynamic compromise in pediatric heart transplant recipients: A multi-institutional study. J Heart Lung Transpl 2001; 20: 279.
7. Manchanda PK, Mittal RD. Analysis of cytokine gene polymorphisms in recipient's matched with living donors on acute rejection after renal transplantation. Mol Cell Biochem 2008; 311: 57.
8. Shahbazi M, Fryer AA, Pravica V, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002; 13: 260.
9. Asderakis A, Sankaran D, Dyer P, et al. Association of polymorphisms in the human interferon-gamma and interleukin-10 gene with acute and chronic kidney transplant outcome: The cytokine effect on transplantation. Transplantation 2001; 71: 674.
10. Zheng HX, Burckart GJ, McCurry K, et al. Interleukin-10 production genotype protects against acute persistent rejection after lung transplantation. J Heart Lung Transplant 2004; 23: 541.
11. Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003; 349: 2201.
12. Girnita DM, Brooks MM, Webber SA, et al. Genetic polymorphisms impact the risk of acute rejection in pediatric heart transplantation: A multi-institutional study. Transplantation 2008; 85: 1632.
13. Auerbach SR, Manlhiot C, Reddy S, et al. Recipient genotype is a predictor of allograft cytokine expression and outcomes after pediatric cardiac transplantation. J Am Coll Cardiol 2009; 53: 1909.
14. Girnita DM, Webber SA, Ferrell R, et al. Disparate distribution of 16 candidate single nucleotide polymorphismsamongracialandethnic groups of pediatric heart transplant patients. Transplantation 2006; 82: 1774.
15. Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1.
16. Chai JG, Bartok I, Chandler P, et al. Anergic T cells act as suppressor cells in vitro and in vivo. Eur J Immunol 1999; 29: 686.
17. Levings MK, Bacchetta R, Schulz U, et al. The role of IL-10 and TGFbeta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 2002; 129: 263.
18. Roncarolo MG, Bacchetta R, Bordignon C, et al. Type 1 T regulatory cells. Immunol Rev 2001; 182: 68.
19. Ho AS, Moore KW. Interleukin-10 and its receptor. Ther Immunol 1994; 1: 173.
20. de Vries JE. Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann Med 1995; 27: 537.
21. Oh SI, Kim IW, Jung HC, et al. Correlation of Fas and Fas ligand expression with rejection status of transplanted heart in human. Transplantation 2001; 71: 906.
22. Perez EC, Shulzhenko N, Morgun A, et al. Expression of Fas, FasL, and soluble Fas mRNA in endomyocardial biopsies of human cardiac allografts. Hum Immunol 2006; 67: 22.
23. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997; 34: 577.
24. Sibley K, Rollinson S, Allan JM, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003; 63: 4327.
25. Cailhier JF, Laplante P, Hebert MJ. Endothelial apoptosis and chronic transplant vasculopathy: Recent results, novel mechanisms. Am J Transplant 2006; 6: 247.
26. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343.
27. Pethig K, Heublein B, Hoffmann A, et al. ACE-gene polymorphism is associated with the development of allograft vascular disease in heart transplant recipients. J Heart Lung Transplant 2000; 19: 1175.
28. Hsu DT, Naftel DC, Webber SA, et al. Lessons learned from the pediatric heart transplant study. Congenit Heart Dis 2006; 1: 54.
29. Stevens A, Soden J, Brenchley PE, et al. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003; 63: 812.
30. Sun T, Zhou Y, Li H, et al. FASL-844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 2005; 202: 967.